Compare HTOO & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTOO | BIAF |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 9.2M |
| IPO Year | 2020 | 2022 |
| Metric | HTOO | BIAF |
|---|---|---|
| Price | $2.04 | $7.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 33.5K | ★ 7.0M |
| Earning Date | 02-28-2023 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,900,000.00 |
| Revenue This Year | $4,832.46 | $20.95 |
| Revenue Next Year | $81.82 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 14.49 |
| 52 Week Low | $1.80 | $0.33 |
| 52 Week High | $5.42 | $20.35 |
| Indicator | HTOO | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 41.91 | 53.42 |
| Support Level | $1.80 | $1.07 |
| Resistance Level | $2.75 | $12.48 |
| Average True Range (ATR) | 0.21 | 1.56 |
| MACD | -0.01 | -0.37 |
| Stochastic Oscillator | 7.03 | 28.16 |
Fusion Fuel Green PLC is a provider of full-service energy engineering and advisory solutions, specializing in green hydrogen and industrial gas applications. It offers a broad portfolio of services, including the design, supply, installation and maintenance of energy systems, as well as the transport and distribution of liquefied petroleum gas. The company serves a diverse customer base spanning commercial buildings, mixed-use developments, heavy industries, and food service sectors. The group currently derives revenue by providing comprehensive solutions for the liquefied petroleum gas (LPG) industry, which includes the supply, installation, and maintenance of LPG systems, as well as transportation and delivery of LPG in both bulk and cylinder formats. It earns majority revenue from UAE.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.